These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 37104648)

  • 1. Complement Inhibitors in the Management of Complement-Mediated Hemolytic Uremic Syndrome and Paroxysmal Nocturnal Hemoglobinuria.
    Begum F; Khan N; Boisclair S; Malieckal DA; Chitty D
    Am J Ther; 2023 May; 30(3):e209-e219. PubMed ID: 37104648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future.
    Risitano AM; Marotta S
    Semin Immunol; 2016 Jun; 28(3):223-40. PubMed ID: 27346521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosing Patterns of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab in the United States: A Retrospective Claims-Based Analysis.
    Cheng WY; Fishman J; Yenikomshian M; Mahendran M; Kunzweiler C; Vu JD; Duh MS
    Adv Ther; 2024 Jan; 41(1):413-430. PubMed ID: 37999832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-complement Treatment for Paroxysmal Nocturnal Hemoglobinuria: Time for Proximal Complement Inhibition? A Position Paper From the SAAWP of the EBMT.
    Risitano AM; Marotta S; Ricci P; Marano L; Frieri C; Cacace F; Sica M; Kulasekararaj A; Calado RT; Scheinberg P; Notaro R; Peffault de Latour R
    Front Immunol; 2019; 10():1157. PubMed ID: 31258525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atypical and secondary hemolytic uremic syndromes have a distinct presentation and no common genetic risk factors.
    Le Clech A; Simon-Tillaux N; Provôt F; Delmas Y; Vieira-Martins P; Limou S; Halimi JM; Le Quintrec M; Lebourg L; Grangé S; Karras A; Ribes D; Jourde-Chiche N; Rondeau E; Frémeaux-Bacchi V; Fakhouri F
    Kidney Int; 2019 Jun; 95(6):1443-1452. PubMed ID: 30982675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria.
    Heo YA
    Drugs; 2022 Dec; 82(18):1727-1735. PubMed ID: 36459381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
    Wong EK; Kavanagh D
    Transl Res; 2015 Feb; 165(2):306-20. PubMed ID: 25468487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The burden of illness in patients with paroxysmal nocturnal hemoglobinuria receiving treatment with the C5-inhibitors eculizumab or ravulizumab: results from a US patient survey.
    Dingli D; Matos JE; Lehrhaupt K; Krishnan S; Yeh M; Fishman J; Sarda SP; Baver SB
    Ann Hematol; 2022 Feb; 101(2):251-263. PubMed ID: 34973099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand.
    Fox LC; Cohney SJ; Kausman JY; Shortt J; Hughes PD; Wood EM; Isbel NM; de Malmanche T; Durkan A; Hissaria P; Blombery P; Barbour TD
    Nephrology (Carlton); 2018 Jun; 23(6):507-517. PubMed ID: 29419916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological and clinical profile of ravulizumab 100 mg/mL formulation for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
    Ariceta G
    Expert Rev Clin Pharmacol; 2023 May; 16(5):401-410. PubMed ID: 37128905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy.
    Versino F; Fattizzo B
    Int J Lab Hematol; 2024 May; 46 Suppl 1():43-54. PubMed ID: 38622956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating ravulizumab for the treatment of children and adolescents with paroxysmal nocturnal hemoglobinuria.
    Yoo JJ; Chonat S
    Expert Rev Hematol; 2022 May; 15(5):385-392. PubMed ID: 35502699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria.
    Scheinberg P; Clé DV; Kim JS; Nur E; Yenerel MN; Barcellini W; Bonito D; Giai V; Hus M; Lee Y; Lekue CB; Panse J; Ueda Y; Buatois S; Gentile B; Kiialainen A; Patel H; Sreckovic S; Uguen M; Edwards J; Nagy Z; Kulasekararaj AG
    Am J Hematol; 2024 Sep; 99(9):1757-1767. PubMed ID: 38924124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How I treat paroxysmal nocturnal hemoglobinuria.
    Brodsky RA
    Blood; 2021 Mar; 137(10):1304-1309. PubMed ID: 33512400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost burden of breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria receiving ravulizumab versus eculizumab.
    Tomazos I; Sierra JR; Johnston KM; Cheung A; Brodsky RA; Weitz IC
    Hematology; 2020 Dec; 25(1):327-334. PubMed ID: 32856539
    [No Abstract]   [Full Text] [Related]  

  • 16. [HELLP syndrome and hemolytic uremic syndrome during pregnancy: two disease entities, same causation. Case report and literature review].
    Mancini A; Ardissino G; Angelini P; Giancaspro V; La Raia E; Nisi M; Proscia A; Tarantino G; Vitale O; D'elia F
    G Ital Nefrol; 2019 Apr; 36(2):. PubMed ID: 30983177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eculizumab and Beyond: The Past, Present, and Future of Complement Therapeutics.
    Patriquin CJ; Kuo KHM
    Transfus Med Rev; 2019 Oct; 33(4):256-265. PubMed ID: 31703946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy.
    Wright RD; Bannerman F; Beresford MW; Oni L
    BMC Nephrol; 2020 Jun; 21(1):245. PubMed ID: 32605540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria.
    Peipert JD; Kulasekararaj AG; Gaya A; Langemeijer SMC; Yount S; Gonzalez-Fernandez FA; Ojeda Gutierrez E; Martens C; Sparling A; Webster KA; Cella D; Tomazos I; Ogawa M; Piatek CI; Wells R; Sicre de Fontbrune F; Röth A; Mitchell L; Hill A; Kaiser K
    PLoS One; 2020; 15(9):e0237497. PubMed ID: 32886668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drugs that inhibit complement.
    Schrezenmeier H; Höchsmann B
    Transfus Apher Sci; 2012 Feb; 46(1):87-92. PubMed ID: 22169380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.